The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

Funding sources: This investigated initiated research was supported by Pfizer bv, the Netherlands, with an unrestricted research grant. The funder had no role in study design, data collection, data analysis, data interpretation, manuscript preparation and/or publication decisions. Conflicts of interest: P.I.S. acted as a consultant for LEO Pharma (about Dovobet), AbbVie (about biosimilars) and Novartis (about omalizumab) in the past. P.I.S. received an independent research grant from Schering Plough and from LEO Pharma (adherence project) in the past. P.I.S. is involved in performing clinical trials with many pharmaceutical industries. M.A.deR. received honoraria for participating in advisory boards from Abbott, Amgen, Artax, Biogen Idec, Centocor, Eli Lilly, GSK, Janssen Cilag, LEO Pharma, MSD, Novartis Pharma, Pfizer, Roche, Sandoz, Waldmann and Xenon Pharma. The Department of Dermatology received an unrestricted grant in the past from Schering Plough, and an educational research grant from Pfizer. J.deK. is joint copyright owner of the Dutch version of the Skindex‐29.